Printer Friendly

Par, MN to develop injectables.

SPRING VALLEY, N.Y. -- Par Pharmaceutical Cos. has entered into an alliance with MN Pharmaceuticals for the development of generic injectable pharmaceuticals. Par and Istanbul-based MN will work on as many as 10 products.

"We are pleased to enter into this partnership. MN is one of Turkey's leading and oldest pharmaceutical companies," comments Par president and chief executive officer Scott Tarriff.

MN will be responsible for developing and manufacturing all products covered under the agreement; Par will provide regulatory affairs support and submit abbreviated new drug applications (ANDAs) to the Food and Drug Administration.

Par will also be responsible for litigation expenses that may arise from the ANDA submissions. Par will have exclusive rights to market, sell and distribute products in the United States.

COPYRIGHT 2005 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Par Pharmaceutical Inc., MN Pharmaceuticals
Publication:Chain Drug Review
Article Type:Brief Article
Geographic Code:7TURK
Date:Nov 21, 2005
Previous Article:Judge backs Teva exclusivity claim.
Next Article:Wyeth clears the way for generic Effexor.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters